NCT03026881

A Study of Fluzoparib Given in Combination With Apatinib and Paclitaxel in Gastric Cancer Patients

An Open, Non-randomised, Multi-centre Phase I Study to Assess the Safety and Efficacy of Fluzoparib Given in Combination With Apatinib and Paclitaxel in the 2nd Line Treatment of Patients With Recurrent or Metastatic Gastric Cancer

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (estimated)
• Sponsor: Jiangsu HengRui Medicine Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Fluzoparib is an oral potent, selective PARP-1 and PARP-2 inhibitor; Apatinib is an oral selective VEGFR inhibitor. This open-label, dose finding phase I trial studies the tolerability and the best dose of Fluzoparib in combination with apatinib and paclitaxel and to see how well this three drugs work together in the treatment of patients with recurrent and metastatic gastric cancer who progress following first-line therapy. The safety and efficacy of fluzoparib in combination with apatinib and paclitaxel will be explored.

Conditions

• Recurrent and Metastatic Gastric Cancer

Interventions

Type	Name	Description
DRUG	Fluzoparib	Fluzoparib either at 20,30,40mg twice daily,capsule oral.
DRUG	Apatinib	Oral
DRUG	Paclitaxel	Intravenous injection

Timeline

• Start date: 2017-01-01
• Primary completion: 2018-04-01
• Completion: 2018-06-01
• First posted: 2017-01-20
• Last updated: 2017-03-07

Locations

1 site across 1 country: China